Format

Send to

Choose Destination
Vaccine. 2015 Jan 1;33(1):73-5. doi: 10.1016/j.vaccine.2014.09.035. Epub 2014 Oct 8.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Author information

1
DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. Electronic address: brightoncollaborationv3swg@gmail.com.
2
DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
3
DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
4
Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, P.O. Box 100266, Gainesville, FL 32610, USA.
5
International AIDS Vaccine Initiative, New York, NY, USA; U.S. Military HIV Research Program (MHRP), Bethesda, MD 20817, USA.
6
PaxVax, San Diego, CA 92121, USA.
7
Laboratory of Retroviruses, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA.
8
Division of Infectious Disease, Jordan University Hospital, Amman, Jordan.
9
Paul-Ehrlich-Institut, 63225 Langen, Germany.
10
Independent Adviser (formerly of National Institute for Biological Standards and Control, Potters Bar, EN6 3QG, UK).
11
Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA.
12
Division of AIDS, National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, Bethesda, MD 20892, USA.
13
Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Service, Cape Town, South Africa.

Abstract

Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed.

KEYWORDS:

Immunization; Safety; Vaccines; Viral Vector

PMID:
25305565
PMCID:
PMC4568939
DOI:
10.1016/j.vaccine.2014.09.035
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center